<DOC>
	<DOCNO>NCT01423032</DOCNO>
	<brief_summary>Bendamustine demonstrate clinical activity pre-treated hematological malignancy due unique mechanism action distinct standard alkylating agent . This study assess efficacy patient chronic lymphocytic leukemia pre-treated alkylator , comparison fludarabine . Patients relapse chronic lymphocytic leukemia require treatment one previous systemic regimen ( usually chlorambucil-based ) randomize either receive bendamustine 100 mg/m² day 1 2 4-week cycle , standard fludarabine treatment consist 25 mg/m² day 1 5 every four week . The primary objective achieve non-inferior progression-free survival bendamustine .</brief_summary>
	<brief_title>Bendamustine Versus Fludarabine Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>histologically immunologically confirm chronic Bcell leukemia refractory ( i.e . response progression initial chemotherapy ) relapse situation firstline treatment regimen disease stage IIIV accord Rai B/C accord Binet staging system , respectively Eastern Cooperative Oncology Group ( ECOG ) performance status 3 well negative pregnancy test/ adequate method contraception TCLL , PLL ( prolymphocytic leukemia ) presence Richter 's transformation firstline treatment contain either fludarabine bendamustine acute infection distinctly reduce organ function preclude application chemotherapy , pulmonary , heart , liver ( total bilirubin &gt; 5mg/dl ) , renal system ( creatinine &gt; 2 mg/dl ) , metabolic disorder secondary malignancy ( except curative treat basal cell carcinoma cervical cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>relapse</keyword>
</DOC>